The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Bimekizumab Promising for PsA

Bimekizumab Promising for PsA

December 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic arthritis (PsA).1

You Might Also Like
  • Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Upadacitinib Promising for RA Patients
Also By This Author
  • Risankizumab May Improve Symptoms of PsA

In the study, 206 patients with active PsA were randomized into five groups to receive either 16 mg bimekizumab, 160 mg bimekizumab, 160 mg bimekizumab with a 320 mg bimekizumab loading dose, 320 mg bimekizumab or placebo every four weeks for 12 weeks. The study’s primary endpoint was the ACR50 response at Week 12.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At baseline, patients had to have a swollen joint count of at least three out of 76, a tender joint count of three out of 78 and fulfill the CASPAR criteria. Nineteen percent of patients had prior exposure to tumor necrosis factor-alpha inhibitors.

After Week 12, placebo-treated patients and 16 mg bimekizumab-treated patients were re-randomized to receive 160 mg or 320 mg bimekizumab. All other patients remained on their previous doses.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
More than 91% of patients completed the double-blind and dose-blind periods, with demographics and baseline disease characteristics balanced across groups.

At Week 12, patients showed a statistically significant dose response for ACR50. Additionally, significantly more bimekizumab-treated patients than placebo-treated patients achieved ACR20, ACR50 and PASI90 (in patients with a body surface area of at least 3% at baseline). Patients who continued their initial bimekizumab dose had increased response rates up to Week 24 for ACR 20, ACR50, ACR70, PASI75, PASI90, MDA and enthesitis resolution. These responses were sustained throughout the study and were comparable across the three highest dosed groups at Week 48.

Treatment-emergent adverse events showed no apparent dose relationship. Serious adverse events were seen in 4.4% of patients up to Week 48. The most common adverse event was nasopharyngitis, occurring in 12.1% of patients. Oral candidiasis was also reported in 4.9% of bimekizumab-treated patients. No cases of inflammatory bowel disease, major adverse cardiac events or death were reported.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Ritchlin CT, Kavanaugh A, Merola JF, et al. Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: Results from a 48-week phase 2b, randomized, double‑blind, placebo-controlled, dose-ranging study [abstract]. Arthritis Rheumatol. 2018 Oct; 70(suppl 10).

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Bimekizumab, Psoriatic Arthritis

You Might Also Like:
  • Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • Upadacitinib Promising for RA Patients
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)